SLC3A2 and neoplasm: To better stratify patient’s death risk, numerous clinical and biological prognostic predictors have been identified, including Rai and Binet staging systems [8,9], lactate dehydrogenase and β2-microglobulin serum levels [10], tumour genomic aberrations [del(11q), del(13q), del(17p), 12 trisomy)] [11], the mutational status of the immunoglobulin heavy-chain variable region genes (IGHV) [12,13], protein expression (CD38, ZAP-70) [12,14], and the mutational status of the TP53 tumour-suppressor gene [15].